医药CMO/CDMO
Search documents
同和药业(300636.SZ):CMO/CDMO业务二季度有所增长,未来可期
Ge Long Hui· 2025-09-01 07:23
Core Viewpoint - The company has reported growth in its CMO/CDMO business in the second quarter and anticipates further growth in the future [1] Group 1: Business Performance - The CMO/CDMO business has seen an increase in new projects in recent years, despite some older projects gradually exiting the market [1] - The company aims to actively serve existing projects while aggressively exploring new projects to compensate for the decline in orders from older projects [1] Group 2: Future Outlook - The CMO/CDMO business is expected to achieve rapid growth in 2027 and 2028 [1]